BACKGROUND: Kanglaite (KLT) is a botanically sourced, molecularly targeted agent that is prepared as a microemulsion for IV use. The active substance is extracted from the herb Semen coicis. OBJECTIVE: The aim of this study was to evaluate the effeCtiveness and tolerability of KLT injection in patients with primary non-small cell lung cancer (NSCLC). manually searched 20 Chinese-language oncology journals to identify randomized controlled trials (RCTs) of KLT injection plus chemotherapy versus chemotherapy alone, regardless of their having been published or not, blinding, duration of treatment, or duration of follow-up. The quality of the included trials was assessed using the method recommended by The Cochrane Collaboration. The studies were assigned to 1 of the following 3 categories: A = all quality criteria met, low risk of bias; B = ; : 0: 1 of the quality criteria only partially met, moderate risk of bias; or C = ;:0:1 of the quality criteria not met, high risk of bias. If heterogeneity existed among subgroups, then overall results were calculated based on a random-effects model; otherwise, a fixedeffects model was used.
analyses performed using both fixed-and random-effects models revealed that compared with chemotherapy alone, KLT injection plus chemotherapy improved the response rate (relative risk [RR}, 1.34; 95% CI, 1.19-1.51 and RR, 1.35; 95% CI, 1.20-1.51, respectively) and quality of life as measured by an increase ;::0:10 points in the Karnofsky Performance Status score (RR, 2.05; 95% CI, 1.60-2.64). KLT injection plus chemotherapy was associated with improvement in the symptoms of cough, dyspnea, chest pain, fatigue, and anorexia. KLT injection plus chemotherapy was also associated with significant reduction in the incidence of the following adverse events (AEs) based on the fixed and random effects models, respectively: grade II to IV leukopenia (RR, 0.29; 95% CI, 0.22-0.39 and RR, 0.33; 95% CI, 0.22-0.48), anemia (RR, 0.54; 95% CI, 0.42-0.70 and RR, 0.55; 95% CI, 0.40-0.76), thrombocytopenia (RR, 0.39;
INTRODUCTION
Lung cancer is the leading cause of cancer-related mortality in the United States. l In 2005, 172,570 new cases of lung cancer were diagnosed and 163,510 resulted in death. When lung cancer patients are found unsuitable for surgery at diagnosis, chemotherapy remains a treatment option. Histologically,~80% of these tumors are of the non-small cell type, including adenocarcinomas and squamous cell and large cell carcinomas. Non-small cell lung cancer (NSCLC) is the main cause of cancer-related deaths. l In advanced-stage NSCLC, chemotherapy prolongs survival and improves patient quality of life, but its effectiveness is not completely satisfactory.
Kanglaite (KLT) (Zhejiang Kanglaite Group Co. Ltd., Hangzhou, China) is a botanically sourced, molecularly targeted agent that is prepared as a microemulsion for IV use. The active substance is extracted from the herb Semen micis. It is used in combination with chemotherapy to minimize toxic reactions and enhance the effect of chemotherapy. In 1995, KLT patent certificates were granted in China. In August 1997, Phase III clinical trials were completed and KLT was officially launched in China after final approval from the Ministry of Public Health. 2 Since 1997, >500,000 cancer patients in >2000 large-and medium-sized hospitals in China have been treated with KLT.
A Semen coicis extract was found to suppress the growth of squamous lung cancer cells. 3 KLT decreased the number of G 21M phase cells, suppressed the proliferation of 382 CURRENT THERAPEUTIC RESEARCH analyses performed using both fixed-and random-effects models revealed that compared with chemotherapy alone, KLT injection plus chemotherapy improved the response rate (relative risk [RR}, 1.34; 95% CI, 1.19-1.51 and RR, 1.35; 95% CI, 1.20-1.51, respectively) and quality of life as measured by an increase ;::0:10 points in the Karnofsky Performance Status score (RR, 2.05; 95% CI, 1.60-2.64). KLT injection plus chemotherapy was associated with improvement in the symptoms of cough, dyspnea, chest pain, fatigue, and anorexia. KLT injection plus chemotherapy was also associated with significant reduction in the incidence of the following adverse events (AEs) based on the fixed and random effects models, respectively: grade II to IV leukopenia (RR, 0.29; 95% CI, 0.22-0.39 and RR, 0.33; 95% CI, 0.22-0.48), anemia (RR, 0.54; 95% CI, 0.42-0.70 and RR, 0.55; 95% CI, 0.40-0.76), thrombocytopenia (RR, 0.39;
A Semen coicis extract was found to suppress the growth of squamous lung cancer cells. 3 KLT decreased the number of G 21M phase cells, suppressed the proliferation of cancer cells, and induced apoptosis of cancer cells, actions that constitute an important mechanism of the antitumor action of KiT. 4 KiT was found to be effective in reversing multiple-drug resistance of cells and increasing the sensitivity of mouse cancer cells to chemotherapeutic agents. s KiT injection might have a direct effect on cancer cell death and improvement of patients' immune function, symptoms, and quality of life. 6 A Cochrane protocol focused on symptom palliation of patients with lung cancer rather than effectivenessJ To date, no systematic review or meta-analysis of the effectiveness of KLT injection in patients with primary NSCLC has been done.
The aim of this meta-analysis was to evaluate the effectiveness and tolerability of KiT injection plus chemotherapy versus chemotherapy alone for patients with NSCLC.
MATERIALS AND METHODS

STUDY DESIGN
Only randomized controlled trials (RCTs) were eligible for this review; blinding, language, published or not, duration of treatment, and the duration of follow-up were not considered. Uncontrolled and observational studies were excluded.
PATIENTS
Patients were eligible for the study if they had primary NSCLC that was confirmed cytologically, pathologically, or by computed tomography or if they had inoperable stage II to IV cancer or stage II cancer and had refused surgery. Patients with a Karnofsky Performance Status (KPS) scores 250 and an expected survival time of 23 months who were aged 218 years were also eligible. Finally, patients not treated with chemotherapy or radiotherapy who had not participated in a trial for 22 months were also eligible.
Patients were excluded from the study if they had liver, brain, or bone metastasis (although asymptomatic patients were eligible); severe heart, hepatic, or renal disease; markedly abnormal blood biochemistry findings; or hepatic or renal dysfunction. Patients who had just undergone surgery or radiotherapy treatment were also excluded.
INTERVENTIONS
The trial groups received KLT injection plus chemotherapy and the control groups received chemotherapy alone, regardless of the duration of treatment or follow-up. The basic treatment in both trial and control groups was identical except for KiT injection.
OUTCOME MEASURES
Mortality Rate
Mortality rate at the end of treatment or follow-up was calculated.
Response Rate
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MATERIALS AND METHODS
STUDY DESIGN
PATIENTS
INTERVENTIONS
OUTCOME MEASURES
Mortality Rate
Response Rate
Response Evaluation Criteria in Solid Tumors, formulated by the World Health Organization (WHO), was used to evaluate the response rate. 9 Based on the degree of tumor absorption, response was classified as follows: (1) complete response (CR) = chest radiograph or computed tomography and/or fiber bronchoscopy revealed complete absorption of the lesion; (2) partial response (PR) = lesion decreased by ;:::50% but~99%; (3) no change = lesion decreased by <50% or increased by <25%; and (4) progressive disease = lesion increased by >25% after treatment. Based on the comparison of chest radiograph or computed tomography before and after treatment, the response rate was defined as CR + PR. 8 
Quality-of-Life Improvement
Quality of life before and after treatment was assessed using the KPS. Only data for patients whose KPS scores improved by ;:::10 points (the minimal clinically significant difference) after treatment were extracted.
Symptom Improvement
The percentage of patients exhibiting improvement in the symptoms of cough, hemoptysis, chest pain, fever, fatigue, and anorexia was assessed. We also calculated the percentage of patients whose symptoms resolved completely. Improvement in symptoms was assessed according to the information provided in each included study.
Specifically, for the pooled analysis of the trials in which symptom improvement was reported, symptoms were scored according to their degree of severity (ie, grades 1-III). For the symptoms of cough, chest pain, and dyspnea, grade I was assigned when the symptoms did not influence daily life, and grade III was assigned when the symptoms were severe, with a marked influence on daily life; symptoms between grade I and III were assigned grade II. For hemoptysis, sputum with blood was assigned grade I, sputum with blood clots or sputum with~10 mUd of blood was assigned grade II, and extremely bloody sputum or sputum with> 10 mUd of blood was assigned grade III. A reduction of more than two thirds in the total score of clinical symptoms was considered improvement, a reduction of no more than two thirds but greater than one third was considered partial improvement, and an unchanged total score or a reduction of no more than one third was considered stable disease.
ADVERSE EVENTS
Adverse events (AEs) were evaluated at the completion of treatment and included bone marrow suppression (leukopenia, anemia, and thrombocytopenia), nausea and vomiting, phlebitis, hepatic dysfunction, and renal dysfunction. According to the WHO grading criteria for acute and subacute toxicity of anticancer dtugs,1O we only calculated AEs of grades II to IV. If patients withdrew from the study due to an AE, we also included these AEs.
LITERATURE COLLECTION
We electronically searched literature of the China Narional Knowledge Infrastructure (Chinese language, 1979-March 2008), CBMdisc (Chinese, 1978-March 2008), The Cochrane Library (English, Issue 4, 2007) , MEDLINE (English, 1966 -March 2008 , and EMBASE (English, 1984 -March 2008 . The reference lists of relevant trials were obtained. We also collected data from ongoing trials documented in Current Controlled Trials (www.controlled-trials.com) and Clinical Trials (www.clinicaltrials.gov). In ad-
384
CURRENT THERAPEUTIC RESEARCH absorption of the lesion; (2) partial response (PR) = lesion decreased by ;:::50% but~99%; (3) no change = lesion decreased by <50% or increased by <25%; and (4) progressive disease = lesion increased by >25% after treatment. Based on the comparison of chest radiograph or computed tomography before and after treatment, the response rate was defined as CR + PR. 8 
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QUALITY ASSESSMENT AND DATA EXTRACTION
Trial Selection
To select eligible studies, one author (X.i.) independently reviewed the title, abstract, and key words of every retrieved record, and another author (G.W.) checked the results. Full-text articles were retrieved for futther assessment if the information available suggested that the study: (1) included patients with NSCLC; (2) compared KLT injection plus chemotherapy with chemotherapy alone; (3) randomly assigned patients to the comparison groups; and (4) included the outcome measutes listed previously. Differences were resolved by discussion.
Quality Assessment
The quality of the trials was assessed according to the Cochrane Collaboration's criteria11: (1) minimization of selection bias (ie, were the randomization procedure and the allocation concealment adequate); (2) minimization of performance bias (ie, were the patients who received treatment and people who administered the treatment blinded to the interventions); (3) minimization of attrition bias (ie, were withdrawals and dropouts completely described and was the analysis based on intent to treat [ITT}); and (4) minimization of detection bias (ie, were outcome assessors blinded to the interventions). Based on these criteria, the studies were broadly subdivided into the following 3 categories: A = all quality criteria met, low risk of bias; B = :2:1 of the quality criteria only partially met, moderate risk of bias; and C = :2: 1 criteria not met, high risk of bias.
Each trial was assessed independently by one author (X.i.) and was checked by another author (G.W.). Differences were resolved by discussion.
Data Extraction
Data from each included trial were extracted independently by one author (X.L.) and checked by another author (G.W.) using a standard extraction form. The form included the following items: 
QUALITY ASSESSMENT AND DATA EXTRACTION
Trial Selection
Quality Assessment
Data Extraction
Data from each included trial were extracted independently by one author (X.L.) and checked by another author (G.W.) using a standard extraction form. The form included the following items:
• General informarion: published/unpublished; language; aurhors; article ritle; journal title, year, volume, issue, and page numbers; and funding source; • Trial design: predetermined sample size, generation of randomization sequence, allocation concealment method, blinding of information, statistical methods, and attrition; • Participants: diagnostic criteria, total number of patients and number of patients in the comparison groups, baseline characteristics (eg, age, gender), inclusion criteria, exclusion criteria, and study settings; • Intervention: type of chemotherapy regimen, duration, time, and dose; co-intervention; control; withdrawals, dropouts, and lost to follow-up; and • Outcome: outcomes at the end of treatment. The number and type of AEs were also extracted. If the aforementioned data were not available in the trial report, further information was sought by corresponding with the original principal investigator.
Data Analysis
Data were analyzed using MetaView 4.2.8 in Review Manager 4.2 (Cochrane collaboration, Oxford, United Kingdom). Meta-analysis was conducted by pooling the different chemotherapy regimens combined with KLT injection and comparing these with chemotherapy regimens alone for an overall analysis; however, the analysis was divided according to subgroups that were formed based on chemotherapy regimens. Sensitivity analyses were conducted by excluding lowquality trials. Analyses were conducted using the ITT principle when possible. Relative risk (RR) was used to analyze dichotomous data. If heterogeneity existed among subgroups, then overall results were calculated based on the random effect model; otherwise, the fixed effect model was used. The random effect model was also used to check whether its use might change the direction of the results in cases where heterogeneity was not tested. Heterogeneity was tested using the z score and X 2 , and P < 0.1 was considered statistically significant.
RESULTS
Electronic database searches yielded 596 citations. A title review eliminated 377 manuscripts; 219 citations were marked for further evaluation. Finally, we identified 26 trials l2 -37 that met the inclusion and exclusion criteria. All of the included studies were published in China. A diagram of the meta-analysis is shown in Figure 1 .
CHARACTERISTICS OF THE INCLUDED TRIALS
All of the included trials met the inclusion criteria. The baseline characteristics of the trial and control groups in the included trials were comparable. All the patients in the included trials had NSCLC that was confirmed cytologically or pathologically.
Interventions and outcome measures used in the included trials are listed 1D Table 1 . 12 -37 No trial reported the outcome measure of mortality.
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Data Analysis
RESULTS
CHARACTERISTICS OF THE INCLUDED TRIALS
Interventions and outcome measures used in the included trials are listed 1D Table 1 . 12 -37 No trial reported the outcome measure of mortality. Potentially relevant RCTs identified and screened for retrieval
Trials that were not RCTs (n =176)
RCTs retrieved for more detailed evaluation (n =43)
RCTs excluded (n =17)
Interventions did not meet the inclusion criteria (7) Participants did not meet the inclusion criteria (4) Duplicate publications (3) Quasi-RCTs (2) Outcome measures did not meet inclusion criteria (1) Potentially appropriate RCTs included in the meta-analysis (n =26)
RCTs excluded from the meta-analysis (n =0)
RCTs included in the meta-analysis
RCTs with usable information, by outcome (n =26) 
QUALITY OF THE INCLUDED TRIALS
The quality of 17 trials was rated C, 9 trials I2 ,13,18-22,24,35 were rated B, and no trial was rated A. Randomization sequences were generated using a computer in 2 trials, 12 13, 18, 20, 21, 25 We obtained randomization details of the trials conducted by Piao et aI12 and Chu et aP3 from Zhejiang Kanglaite Group Co. Ltd. We requested additional information about randomization from the aurhors of all the included trials, and obtained randomization details from the authors of 5 trials. 2o -22 ,24,29 The details are listed in Table II .12-37
META-ANALYSIS RESULTS
Response Rate
The details of the response rates are shown in Figure 2 . Response rate was used as an outcome measure in 22 trials I2 -17 ,19-31,33-35 (Table I) . Heterogeneity was not detected among the subgroups (P = 0.48). Pooled analysis of 9 subgroups revealed that compared with chemotherapy alone, KLT injection plus chemotherapy improved the response rate using both fixed (RR, 1.34; 95% CI, 1.19-1.51) and random effect models (RR, 1.35; 95% CI, 1.20-1.51). Grade C trials were excluded from the sensitivity analysis. The results of the sensitivity analysis were consistent between the fixed (RR, 1.29; 95% CI, 1.07-1.55) and random effect models (RR, 1.33; 95% CI, 1.05-1.68).
A subgroup analysis of 5 trials I2 , 14, 26, 31, 35 suggested that a regimen of KLT injection plus chemotherapy with a regimen of mitomycin with vindesine and cisplatin (MVP) was associated with greater improvement in the response rate (RR, 1.76; 95% CI, 1.34-2.31) than chemotherapy alone.
Another subgroup analysis of 2 trials 21 ,22 found that compared with chemotherapy alone, KLT injection plus chemotherapy with gemcitabine hydrochloride plus cisplatin (GP) was associated with greater improvement in the response rate (RR, 1.75; 95% CI, 1.16-2.64).
Subgroup analysis of 8 trials I5 , 16, 24, 25, 28, 29, 33, 34 found that compared with chemotherapy with vinorelbine plus cisplatin (NP), KLT injection plus NP was associated with greater improvement in the response rate (RR, 1.30; 95% CI, 1.07-1.59).
The improvement in the response rates ( Figure 2 ) with KLT injection plus chemotherapy was not greater than that associated with chemotherapy alone in the following regimens: hydroxycamptothecin + etoposide (VP-16) + cisplatin (HEP); cyclophosphamide + adriamycin + cisplatin (CAP); GP/NP; MVP/cisplatin + VP-16 (EP); mitomycin + adriamycin + cisplatin (MAP)/MVP; cyclophosphamide + epirubicin + cisplatin (CEP); and EP.
Analyses of the MVP, GP, and NP chemotherapy regimen subgroups found a statistical difference between KLT injection plus chemotherapy and chemotherapy alone. Each subgroup included data from > 2 trials, with a sample size ranging from 71 to 275. Meanwhile, the analyses of the other 7 subgroups did not show a statistical difference between the 2 groups with regard to the response rate. Each subgroup in-391 X. Llu ET AL.
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The quality of 17 trials was rated C, 9 trials I2 ,13,18-22,24,35 were rated B, and no trial was rated A. Randomization sequences were generated using a computer in 2 trials, 12 
META-ANALYSIS RESULTS
Response Rate
Analyses of the MVP, GP, and NP chemotherapy regimen subgroups found a statistical difference between KLT injection plus chemotherapy and chemotherapy alone. Each subgroup included data from > 2 trials, with a sample size ranging from 71 to 275. Meanwhile, the analyses of the other 7 subgroups did not show a statistical difference between the 2 groups with regard to the response rate. Each subgroup in-n ID c: Test for heterogeneity: X' = 6.17, df = 1 (P = 0.52), " = 0% Test for overall effect: z = 2.64 (P = 0.008) eluded only 1 trial with sample sizes ranging from 39 to 214. These findings may be due to different chemotherapy regimens being associated with different response rates or to the sample size being too small to detect a difference. Three trials 15 ,34,35 that did not perform ITT analysis reported that KiT improved the response rate. Yang et aP5 reported that 3 patients withdrew from the trial group (2 due to surgery or radiotherapy during the study period and 1 due to financial issues). In addition, 3 patients withdrew from the control group because they had undergone surgery or radiotherapy during the study. An and Yuan 34 reported that 4 patients discontinued therapy due to hearing disorder (2 patients), brain metastasis (1), or hepatic dysfunction (1); another 2 patients died. ] u et aP5 reported that 10 patients in the KiT group and 6 in the control group were lost to follow-up due to complete data being unavailable. The results of ITT analysis did not show statistical differences in the response rate between KiT plus chemotherapy and chemotherapyalone.
Quality-of-Life Improvement
The details of quality-of-life improvement are shown in Figure 3 . Eighteen trials 12 ,14-20,22-24,26-28,31,32,36,37 reported the number of patients with NSCiC who exhibited an improvement of~10 points in their KPS score. Heterogeneity was found among subgroups (P < 0.001); therefore, the random effect model was used for total pooled analysis. Compared with chemotherapy alone, KLT injection plus chemotherapy was associated with an increase in the number of patients with NSCiC with ã 10-point improvement in their KPS score (RR, 2.05; 95% CI, 1.60-2.64). We exeluded trials with a quality grade of C and conducted a sensitivity analysis, which revealed concordant results (RR, 3.17; 95% CI, 2.39-4.20).
One study26 found that KiT plus chemotherapy was associated with an increase in the number of patients with a :2: 1O-point improvement in KPS score. Our meta-analysis found that there was no statistically significant difference between the 2 groups. We found that the incorrect statistical method had been used in the study to analyze the data (ie, the t test was used to analyze dichotomous data).
Two other studies 15 ,18 found that KiT was associated with significant improvement in the KPS score in the absence of ITT analysis. Our ITT analysis showed that there was no statistically significant difference between the trial and control groups (Figure 2 ).
Symptom Improvement
Six trials 12 ,19,27,29,34,36 used improvement in symptoms as an outcome measure and reported the results. Three trials 12 ,19,36 all used the same symptom improvement scale. One triaP6 reported the number of patients whose symptoms resolved completely.
Only data from the 3 trials that used the same scale were pooled (Table III) . The pooled analysis showed that KiT plus chemotherapy was associated with improvement in dyspnea and chest pain but not hemoptysis. For the improvement in cough, the findings from the fixed effect model suggest that KiT injection was effective (RR, 1.36; 95% CI, 1.11-1.67), but those from the random effect model did not find this 397 X. LIU ET AL. eluded only 1 trial with sample sizes ranging from 39 to 214. These findings may be due to different chemotherapy regimens being associated with different response rates or to the sample size being too small to detect a difference.
Three trials 15 ,34,35 that did not perform ITT analysis reported that KiT improved the response rate. Yang et aP5 reported that 3 patients withdrew from the trial group (2 due to surgery or radiotherapy during the study period and 1 due to financial issues). In addition, 3 patients withdrew from the control group because they had undergone surgery or radiotherapy during the study. An and Yuan 34 reported that 4 patients discontinued therapy due to hearing disorder (2 patients), brain metastasis (1), or hepatic dysfunction (1); another 2 patients died. ] u et aP5 reported that 10 patients in the KiT group and 6 in the control group were lost to follow-up due to complete data being unavailable. The results of ITT analysis did not show statistical differences in the response rate between KiT plus chemotherapy and chemotherapyalone.
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Symptom Improvement
Only data from the 3 trials that used the same scale were pooled (Table III) . The pooled analysis showed that KiT plus chemotherapy was associated with improvement in dyspnea and chest pain but not hemoptysis. For the improvement in cough, the findings from the fixed effect model suggest that KiT injection was effective (RR, 1.36; 95% CI, 1.11-1.67), but those from the random effect model did not find this ?" Test for heterogeneity: X 2 = 0.02, df = 1 (P = 0.89), ( effective (RR, 1.31; 95% CI, 0.95-1.81). Sensitivity analysis s' ;gested that KiT was effective (RR, 1.40; 95 % CI, 1.13-1.73). Therefore, KiT plus chemotherapy was considered to be effective in improving cough. One trial 36 also found that KiT injection plus chemotherapy was not associated with the complete resolution of symptoms.
For improvement in fatigue and anorexia, heterogeneity was found among trials; therefore, only the random effect model was used. Pooled analysis showed that KiT + chemotherapy was not effective in improving fatigue or anorexia, whereas sensitivity analysis demonstrated contrary results for both fatigue and anorexia (both, RR, 2.91; 95% CI, 1.72-4.91). Therefore, we considered that KLT was effective in improving fatigue and anorexia (Table III) .
Adverse Events
The details of the AEs are shown in Table IV .
Bone Marrow Suppression
Eight trials 15 ,18,23,25,32,34,35,37 did not report the results with regard to leukopenia. Three trials 14 ,30,35 reported that the leukopenia rate did not meet the WHO grading criteria 8 for acute and subacute toxicity of anticancer drugs. Three trials I7 ,22,23 reported only the total incidence of bone marrow suppression. Thus we could not extract quantitative data. Twelve trials I2 ,13.16,19-21.26-30,33 reported the incidence of grade II to IV leukopenia. The pooled results of those 12 trials suggested that KiT injection plus chemotherapy was associated with a reduction in the incidence of leukopenia in both the fixed (RR, 0.29; 95% CI, 0.22-0.39) and random effect models (RR, 0.33; 95% CI, 0.22-0.48). Grade C trials were eliminated for the sensitivity analysis; the results of sensitivity analysis were in agreement with these results (RR, 0.19; 95% CI, 0.11-0.34).
A 13, 16, 19 reported the incidence of grade II to IV thrombocytopenia. These 4 trials were pooled; KiT plus chemotherapy was associated with a reduction in the incidence of thrombocytopenia in both the fixed (RR, 0.39; 95% CI, 0.21-0.71) and the random effect models (RR, 0.40; 95% CI, 0.21-0.78). A sensitivity analysis was in agreement with this result (RR, 0.34; 95% CI, 0.17-0.67).
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Adverse Events
Bone Marrow Suppression
Eight trials 15 ,18,23,25,32,34,35,37 did not report the results with regard to leukopenia. Three trials 14 ,30,35 reported that the leukopenia rate did not meet the WHO grading criteria 8 for acute and subacute toxicity of anticancer drugs. Three trials I7 ,22,23 reported only the total incidence of bone marrow suppression. Thus we could not extract quantitative data. Twelve trials I2 , 13.16,19-21.26-30,33 reported the incidence of grade II to IV leukopenia. The pooled results of those 12 trials suggested that KiT injection plus chemotherapy was associated with a reduction in the incidence of leukopenia in both the fixed (RR, 0.29; 95% CI, 0.22-0.39) and random effect models (RR, 0.33; 95% CI, 0.22-0.48). Grade C trials were eliminated for the sensitivity analysis; the results of sensitivity analysis were in agreement with these results (RR, 0.19; 95% CI, 0.11-0.34).
A total of 11 trials I4 , 15, 18, 24, 26, 28, 29, 31, 32, 36, 37 did not report their findings with regard to anemia. Six trialsI7.22.23,25.34.35 reported bone marrow suppression findings but not anemia. The quantitative data of 8 trials I2 . 16 ,19-21,30,31,33 were extracted and a pooled analysis was conducted. No heterogeneity was found among the subgroups. The pooled results found that KLT plus chemotherapy was associated with a reduction in the incidence of grade II to IV anemia in both the fixed (RR, 0.54; 95% CI, 0.42-0.70) and random effect models (RR, 0.55; 95% CI, 0.40-0.76). The results of the sensitivity analysis were in agreement with this result (RR, 0.56; 95% CI, 0.43-0.72).
Seven trials 15 ,17,22,23,25,34,35 reported bone marrow suppression findings but not thrombocytopenia. Fourteen trials 14, 15, 18, 20, 24, 26, [28] [29] [30] [31] [32] [33] 36, 37 did not report observations regarding thrombocytopenia. Four trials I2 , 13, 16, 19 reported the incidence of grade II to IV thrombocytopenia. These 4 trials were pooled; KiT plus chemotherapy was associated with a reduction in the incidence of thrombocytopenia in both the fixed (RR, 0.39; 95% CI, 0.21-0.71) and the random effect models (RR, 0.40; 95% CI, 0.21-0.78). A sensitivity analysis was in agreement with this result (RR, 0.34; 95% CI, 0.17-0.67). Nine trials 14 ,17,20,21,23,27,28,30,33 reported the number of patients with grade II to IV nausea and vomiting. There was no statistical difference among the trials with regard to heterogeneity. Pooled analysis found that, compared with chemotherapy alone, KLT injection plus chemotherapy was associated with a reduction in the incidence of nausea and vomiting in both the fixed (RR, 0.44; 95% CI, 0.34-0.57) and random effect models (RR, 0.44; 95% CI, 0.35-0.57); however, sensitivity analysis suggested contradictory results (RR, 0.26; 95% CI, 0.03-2.25). Therefore, there was no statistical difference between KLT plus chemotherapy and chemotherapy alone with regard to improvement in nausea and vomiting. Deng et al 22 reported that 8 of 21 patients (38%) receiving KLT plus chemotherapy and 15 of 22 patients (68%) receiving chemotherapy alone expetienced nausea and vomiting; however, they did not report the incidence of grade II to IV events.
Phlebitis
Pooled in the chemotherapy alone group experienced renal dysfunction, bur the incidence of grade II to IV events was not reported. Deng et aF2 reported the incidence of renal dysfunction but not specifically the incidence of grade II to IV events.
DISCUSSION
KLT injection is a product of traditional Chinese medicine; however, its effectiveness and safety in patients with NSCLC have been tested using Western methodology.3 407 X. Llu ET AL.
Nausea and Vomiting
Nine trials 14 ,17,20,21,23,27,28,30,33 reported the number of patients with grade II to IV nausea and vomiting. There was no statistical difference among the trials with regard to heterogeneity. Pooled analysis found that, compared with chemotherapy alone, KLT injection plus chemotherapy was associated with a reduction in the incidence of nausea and vomiting in both the fixed (RR, 0.44; 95% CI, 0.34-0.57) and random effect models (RR, 0.44; 95% CI, 0.35-0.57); however, sensitivity analysis suggested contradictory results (RR, 0.26; 95% CI, 0.03-2.25). Therefore, there was no statistical difference between KLT plus chemotherapy and chemotherapy alone with regard to improvement in nausea and vomiting. Deng et al 22 reported that 8 of 21 patients (38%) receiving KLT plus chemotherapy and 15 of 22 patients (68%) receiving chemotherapy alone expetienced nausea and vomiting; however, they did not report the incidence of grade II to IV events.
Phlebitis
DISCUSSION
KLT injection is a product of traditional Chinese medicine; however, its effectiveness and safety in patients with NSCLC have been tested using Western methodology.3
Several controlled trials of KLT injection plus chemotherapy versus chemotherapy alone have been conducted in both Asian and American populations. However, because we included only RCTs, no RCTs of US populations were identified. In total, this meta-analysis found KLT injection plus chemotherapy improved the response rate in these patients with NSCLC (RR, 1.34; 95% CI, 1.19-1.51). The subgroups of different chemotherapy regimens led to different conclusions. Subgroups of HEP, CAP, CEP, NP/GP, and MVP/MAP chemotherapy regimens included only 1 trial each; therefore, no statistical differences were found between the KLT plus chemotherapy and chemotherapy alone groups. On the other hand, the subgroups of MVP, GP, and NP regimens included> 1 trial; statistical differences were found between the 2 groups. Therefore, it is possible that the sample size of a single trial was too small to test validity.
The effectiveness of KLT plus chemotherapy in improving the quality of life of patients with NSCLC was found to be highly significant (RR, 2.05; 95% CI, 1.60-2.64). Two trials 1S ,18 found positive conclusions, but the results of ITT analysis in our meta-analysis were negative, suggesting that the loss of patients to follow-up affected the results to some extent. One trial 26 concluded positive results by using inappropriate statistical methods, bur the findings of our meta-analysis were negative. Therefore, the statistical method used was also a factor influencing the results.
KLT plus chemotherapy in this meta-analysis was associated with a significant decrease in the incidence of AEs, including grade II to IV leukopenia, anemia, and thrombocytopenia. This combination therapy was also associated with significant improvement in the symptoms of grade II to IV cough, dyspnea, chest pain, fatigue, and anorexia.
KLT injection plus chemotherapy was not associated with obvious toxicity or AEs. Some patients may experience nausea, low-grade fever, or occasional skin rash or phlebi tis. 12-14, 16,17,19-21 ,23,26-30,33 No significant hepatic or renal dysfunction was found in either KLT injection plus chemotherapy or chemotherapy alone group.
LIMITATIONS
Literature related to KLT therapy in patients with NSCLC was collected by manual and Internet search and by requesting data from pharmaceutical manufacturers. A formal data extraction table was designed to extract data for quantitative analysis. The accuracy of the data extraction was assessed using a second reviewer. The 26 trials included were all published in China. They included 2209 patients with NSCLC. The sample size of each trial varied from 40 to 305 patients. None of the trials had sample sizes determined a priori. The heterogeneity among subgroups might be attributed to differing sample sizes. We found that the positive effect increased with a bigger sample size.
Information about random sequence generation was available for only 10 trials,12,13,18-24,35 while information about allocation concealment was not available for any of the included trials. Therefore, there was a high risk of selection bias and performance bias in this systematic review. Information about blinding was available for only 3 trials I2 ,13,3S; therefore, a high detection bias also existed in this sys-
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CURRENT THERAPEUTIC RESEARCH Several controlled trials of KLT injection plus chemotherapy versus chemotherapy alone have been conducted in both Asian and American populations. However, because we included only RCTs, no RCTs of US populations were identified. In total, this meta-analysis found KLT injection plus chemotherapy improved the response rate in these patients with NSCLC (RR, 1.34; 95% CI, 1.19-1.51). The subgroups of different chemotherapy regimens led to different conclusions. Subgroups of HEP, CAP, CEP, NP/GP, and MVP/MAP chemotherapy regimens included only 1 trial each; therefore, no statistical differences were found between the KLT plus chemotherapy and chemotherapy alone groups. On the other hand, the subgroups of MVP, GP, and NP regimens included> 1 trial; statistical differences were found between the 2 groups. Therefore, it is possible that the sample size of a single trial was too small to test validity.
LIMITATIONS
Information about random sequence generation was available for only 10 trials,12,13,18-24,35 while information about allocation concealment was not available for any of the included trials. Therefore, there was a high risk of selection bias and performance bias in this systematic review. Information about blinding was available for only 3 trials I2 ,13,3S; therefore, a high detection bias also existed in this sys-tematic review. Only 6 trials 12 ,13,15,18,19,35 reported the number of patients who were lost to follow-up or the reasons they were lost to follow-up. Our ITT analysis reversed the original positive results in the case of 3 trials 15 ,25,35 that reported the response rate and 2 trials 14 ,17 that reported improvement in quality of life. In the other trials that did not report the status of loss to follow-up or withdrawal, a high withdrawal bias existed. Only 4 trials 12 ,19,27,36 reported improvement of symptoms, including cough, hemoptysis, dyspnea, chest pain, fatigue, and anorexia. Overall, 11 trials 14 ,16,17,20,21,23,27-30,33 reported AEs occurring in the trial and control groups. The remaining 15 trials did not provide information about AEs. Four trials 12 ,19,27,36 reported the outcome of symptom improvement. Only 3 trials 17 ,22,23 reported the total incidence of bone marrow suppression. No data on leukopenia, anemia, or thrombocytopenia were available. Selection reporting outcome bias led to some unavailability of integrated results. No trial reported the outcome measure of mortality. These conclusions are also limited by the low quality scores of the included trials.
CONCLUSION
This meta-analysis found that, compared with chemotherapy alone, KLT injection plus chemotherapy improved the response rate, quality of life, and symptoms, and decreased the incidence of AEs in these patients with primary NSCLC. tematic review. Only 6 trials 12 ,13,15,18,19,35 reported the number of patients who were lost to follow-up or the reasons they were lost to follow-up. Our ITT analysis reversed the original positive results in the case of 3 trials 15 ,25,35 that reported the response rate and 2 trials 14 ,17 that reported improvement in quality of life. In the other trials that did not report the status of loss to follow-up or withdrawal, a high withdrawal bias existed.
Only 4 trials 12 ,19,27,36 reported improvement of symptoms, including cough, hemoptysis, dyspnea, chest pain, fatigue, and anorexia. Overall, 11 trials 14 ,16,17,20,21,23,27-30,33 reported AEs occurring in the trial and control groups. The remaining 15 trials did not provide information about AEs. Four trials 12 ,19,27,36 reported the outcome of symptom improvement. Only 3 trials 17 ,22,23 reported the total incidence of bone marrow suppression. No data on leukopenia, anemia, or thrombocytopenia were available. Selection reporting outcome bias led to some unavailability of integrated results. No trial reported the outcome measure of mortality. These conclusions are also limited by the low quality scores of the included trials.
This meta-analysis found that, compared with chemotherapy alone, KLT injection plus chemotherapy improved the response rate, quality of life, and symptoms, and decreased the incidence of AEs in these patients with primary NSCLC.
